Searched for
GLAXO SMITHKLINE
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- GSK Consumer Healthcare Q3 profit jumps 25% to Rs 277 croreThe total income of the company rose to Rs 1,274.90 crore as against Rs 1,241.07 crore.
- CCI approves Corona Remedies-GlaxoSmithKline dealDilo-BM, Dilo-DX, Stelbid and Vitneurin brands of GlaxoSmithKline would be acquired by Corona Remedies along with trademark and goodwill.
- India clears foreign investment proposals of GSK, Novartis, MylanIndia has cleared a host of foreign investment proposals including Glaxo SmithKline, Novartis, Mylan, Catholic Syrian Bank and Bandhan Fina...
- Buy Glaxo SmithKline with a target of Rs 2750: Mitesh Thacker'Glaxo SmithKline is a 'BUY' call with a target of Rs 2750 and a stop loss of Rs 2620.'
- GSK Pharma shares slump over 8% ahead of closure of open offerShares of GlaxoSmithKline Pharmaceuticals slumped over 8 per cent as the open offer made by its UK-based parent to acquire additional stake...
- GlaxoSmithkline Healthcare Q1 net up 19 per cent at Rs 132 croreGlaxoSmithkline Consumer Healthcare (GSKCH) today said its net profit rose 19.30 per cent to Rs 131.97 crore for the first quarter ended Ma...
- GlaxoSmithKline Q1 net profit down at Rs 46 lakhGlaxoSmithkline Pharmaceuticals posted a massive decline in its net profit at Rs 46 lakh in the quarter ended March 31, from Rs 161 crore r...
- Piramal Healthcare heavily traded; Glaxo SmithKline need little more volume: Deepak MohoniDeepak Mohoni, Director, trendwatchindia.com spoke to ET Now on stocks and market.
- GSK to launch 'promecta' in India by 2009-endGlaxo SmithKline Pharmaceutical on Thursday said it is looking at launching its patented medicine promecta, used in treatment of depleted p...
- Glaxo SmithKline to axe 6,000 workersGlaxo SmithKline, Britain's biggest pharmaceuticals company, plans to axe around 6,000 jobs around the world as it faces up to the growing ...
- Glaxo SmithKline to axe 6,000 workersGlaxo SmithKline, Britain's biggest pharmaceuticals company, plans to axe around 6,000 jobs around the world as it faces up to the growing ...
- DRL gets ex-Ranbaxy honcho as R&D chiefDr Reddy's Laboratories has announced the appointment of Dr Rajinder Kumar as its president (R&D and commercialization).
Load More
